Public portfolio

Public Portfolio Challenge: Semis + Biotech | Public portfolio

Read the public listing for Public Portfolio Challenge: Semis + Biotech, then open its portfolio dashboard to inspect the creator's strategy and performance mode.

Portfolio mode
Live trading
Created
2026-08-24

Recorded portfolio returns

Metrics computed 2026-10-10T14:08:17.665Z. These are live portfolio observations, not a backtest or a forecast. Returns come from the stored equity history. Review deposits and withdrawals alongside equity-based percentages.

Past week-1.07%
Past month5.06%
Past year4.11%
Since inception4.11%

Creator's public notes

Episode 11 live forward test. On August 26, 2026, the original six-strategy XBI/SMH design was preserved in a separate paper portfolio and this live Public account was replaced with the validated 29-strategy implementation: one central allocator across 26 thesis-approved companies, two global option exits, and 26 company-specific exits. There is no XBI gate, no SMH gate, and no special MRNA or ANET allocation. Each company must be above its own 100-day SMA with positive 63-day momentum. Eligible names compete on 126-day return and are weighted by 63-day return divided by 63-day volatility. Entries are single long calls with 270 to 730 DTE, capped at 6% per company and 45% per rebalance. VIX must be below 35 and option gross exposure must be below 39% before a new buying cycle. Profit, time, and company-level trend exits remain active. Research evidence at the actual $13,500 account size: four of five OOS folds profitable, +25.00% median OOS return, 1.99 median OOS Sortino, and 22.47% worst OOS drawdown. The full March 2022 to April 2026 replay returned +252.37% with a 29.79% maximum drawdown, 30.53% median deployment, 20 of 26 names traded, and 496 simulated option fills. These are historical simulations, not promised returns. Deployment preserved the existing QGEN Dec. 17, 2027 $45 call. A current-book reconciliation at $13,335.02 NAV produced zero orders and $0 estimated cost. Automatic approval is off. Every future live order requires manual approval. Episode 11: https://nexustrade.io/blog/moderna-basically-cured-cancer-i-used-grok-bot-to-create-a-trading-strategy-20260823 Research record: https://github.com/austin-starks/Public-Portfolio-Challenge/blob/main/episode-11/addendum/EPISODE_11_OPTIONS_PORTFOLIO_REDESIGN_20260826.md

Review the portfolio before copying

Open the portfolio dashboard to review the displayed performance mode, observation dates and risk metrics. Historical backtests, paper simulations and live account results represent different evidence.

Review the creator's configured rules and portfolio allocation in the interactive dashboard before creating your own copy.